Status: Recruiting
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Crinecerfont in Participants With Classic Congenital Adrenal Hyperplasia (CAH) Who Are Less Than 4 Years Old
The main objective of this study is to assess the safety and tolerability of crinecerfont in pediatric participants 3 months to \<4 years of age with CAH.
Participants needed: 20
Trial details
Phase: Phase 2Age: 3-47Biological sex: AllType: InterventionalSponsor: Neurocrine Switzerland GmbHUpdated: Sep 16, 2026Locations: 11
Eligibility criteria
Have a medically confirmed diagnosis of classic CAH (salt wasting or simple viri... [+3]
Have a known or suspected diagnosis of any of the other forms of classic CAH. [+2]